CA2398839A1 - Procede et marqueur destines a l'identification de premalignite et de malignite et intervention therapeutique - Google Patents

Procede et marqueur destines a l'identification de premalignite et de malignite et intervention therapeutique Download PDF

Info

Publication number
CA2398839A1
CA2398839A1 CA002398839A CA2398839A CA2398839A1 CA 2398839 A1 CA2398839 A1 CA 2398839A1 CA 002398839 A CA002398839 A CA 002398839A CA 2398839 A CA2398839 A CA 2398839A CA 2398839 A1 CA2398839 A1 CA 2398839A1
Authority
CA
Canada
Prior art keywords
myc
cells
cyclin
gene
ees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002398839A
Other languages
English (en)
Inventor
Sabine Mai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
CancerCare Manitoba
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2398839A1 publication Critical patent/CA2398839A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé permettant l'identification de prémalignité, de malignité et du degré de prémalignité et de malignité d'une cellule par détection de l'amplification génique extrachromosomique et intrachromosomique. L'invention concerne également un marqueur destiné à l'identification de prémalignité, de malignité et du degré de prémalignité et de malignité d'une cellule renfermant une amplification génique extrachromosomique et intrachromosomique. L'invention concerne en outre un outil de diagnostic destiné au diagnostic et au pronostic du cancer du col de l'utérus renfermant une amplification génique extrachromosomique et intrachromosomique d'un gène.
CA002398839A 2000-01-21 2001-01-22 Procede et marqueur destines a l'identification de premalignite et de malignite et intervention therapeutique Abandoned CA2398839A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48928800A 2000-01-21 2000-01-21
US09/489,288 2000-01-21
PCT/US2001/002085 WO2001053536A1 (fr) 2000-01-21 2001-01-22 Procede et marqueur destines a l'identification de premalignite et de malignite et intervention therapeutique

Publications (1)

Publication Number Publication Date
CA2398839A1 true CA2398839A1 (fr) 2001-07-26

Family

ID=23943203

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002398839A Abandoned CA2398839A1 (fr) 2000-01-21 2001-01-22 Procede et marqueur destines a l'identification de premalignite et de malignite et intervention therapeutique

Country Status (4)

Country Link
EP (1) EP1254261A4 (fr)
AU (1) AU2001231056A1 (fr)
CA (1) CA2398839A1 (fr)
WO (1) WO2001053536A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248107A1 (en) 2003-06-09 2004-12-09 Sokolova Irina A. Detection of high grade dysplasia in cervical cells
EP1631686B1 (fr) * 2003-06-09 2012-05-09 Vysis, Inc. Detection de la dysplasie de haut degre dans les cellules cervicales
CN106414501B (zh) 2013-09-26 2020-07-14 凡弗3基因组有限公司 用于病毒相关肿瘤的系统、方法和组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538846A (en) * 1992-09-17 1996-07-23 Meeker; Timothy C. BCL-1 locus nucleic acid probes and assay methods
CA2253002A1 (fr) * 1998-03-25 1999-09-25 Sabine Mai Methode et marqueur pour l'identification de tumeurs premalignes et malignes, et intervention therapeutique

Also Published As

Publication number Publication date
EP1254261A4 (fr) 2004-04-21
EP1254261A1 (fr) 2002-11-06
AU2001231056A1 (en) 2001-07-31
WO2001053536A1 (fr) 2001-07-26

Similar Documents

Publication Publication Date Title
Zhang et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast
US6835541B2 (en) Aberrantly methylated genes as markers of breast malignancy
Du et al. Cooperating cancer-gene identification through oncogenic-retrovirus–induced insertional mutagenesis
KR102240323B1 (ko) 유방암 전이의 진단, 예후 및 치료 방법
JP2008539731A (ja) 癌の診断及び治療のための組成物及び方法
Patterson et al. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas
US20110262464A1 (en) Compositions, Kits, and Methods for the Diagnosis, Prognosis, and Monitoring of Cancer Using GOLPH3
Blanc et al. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model
US7045292B2 (en) Method and marker for identification of pre-malignancy and malignancy and therapeutic intervention
Moul et al. Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas
US20120207755A1 (en) Cancer
JP6566933B2 (ja) ガンを治療するための療法のための標的として使用するためのｆａｌｚ
US20080182250A1 (en) Method for detecting multiple myeloma and method for inhibiting the same
EP1660677A2 (fr) Proteine 2 inductible par l'hypoxie (hig2), nouvelle cible therapeutique potentielle de l'hypernephrome (rcc)
CA2398839A1 (fr) Procede et marqueur destines a l'identification de premalignite et de malignite et intervention therapeutique
US7214488B2 (en) Detection of MECT1-MAML2 fusion products
EP0955383A1 (fr) Procédé et marqueur pour l'identification de la pre-malignité et malignité et leurs utiisations dans les interventions thérapeutiques
US9229003B2 (en) Method for detecting thyroid carcinoma
JP2007528717A (ja) 結腸直腸癌を診断する方法
KR20190005727A (ko) 난소과립막세포암 또는 자궁내막암의 진단 및 치료를 위한 마이크로rna-1236의 용도
JP2007267700A (ja) Ｈｏｘｂ１３遺伝子のメチル化を指標とする腎細胞癌を含む悪性腫瘍の判定方法
Lee et al. nm23-H1 protein expression and gene mutation in 150 patients with non-Hodgkin's lymphomas
Hakozaki et al. Establishment and characterization of a new cell line, FRTK-1, derived from human malignant rhabdoid tumor of the kidney, with overexpression of epidermal growth factor receptor and cyclooxygenase-2
Dyer et al. Chromosomal and molecular alterations in lymphoid malignancies: basic principles and detection methods
WO2005047519A2 (fr) Regulation negative de lsamp et nore1 dans les hypernephromes a cellules claires

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued